Sutro Biopharma paid its 4 named executives $5.0M in total in FY2025 (Dec). CEO Jane Chung, R.Ph. was paid $1.6M of that.
Pay$100 in the stock at the end of FY22 → $14
Pay of each named executive
William J. NewellFormer Chief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
Jane Chung, R.Ph.Chief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
Hans-Peter Gerber, Ph.D.Chief Scientific Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
Gregory ChowChief Financial Officer
| FY2025 (Dec) |
1 year
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $5.6M. CEO pay of Sutro Biopharma for that year is not on file.
- 1Arcus Biosciences
- 2Zymeworks
- 3Nurix Therapeutics
- 4Kura Oncology
- 5Replimune Group
- 6Gossamer Bio
- 7Sutro BiopharmaThis companyNot disclosed
- 8AlectorNot disclosed
- 9Allogene TherapeuticsNot disclosed
- 10Anaptys Bio, Inc.Not disclosed
- 11Atara Biotherapeutics, Inc.Not disclosed
- 12Caribou BiosciencesNot disclosed
- 13G1 Therapeutics, Inc.Not disclosed
- 14Gritstone Bio, Inc.Not disclosed
- 15IGM Biosciences, Inc.Not disclosed
- 16MacrogenicsNot disclosed
- 17Mersana Therapeutics, Inc.Not disclosed
- 18Poseida Therapeutics, Inc.Not disclosed
- 19Sangamo Therapeutics, Inc.Not disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.